Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis
Authors:
Open Access
- 1 February 2019
- Vol. 21 (2) , 172-184
Abstract
No abstract availableKeywords
Funding Information
- Department of Defense (W81XWH-14-1-0403, W81XWH-17-1-0541)
- Department of Defense (W81XWH-14-1-0408)
- nih: national cancer institute (F32 CA168269)
- nih: national cancer institute (PO1CA093900)
- Deutsche Forschungsgemeinschaft (Forschergruppe-1586 SKELMET, SPP-2084 μBONE)
This publication has 43 references indexed in Scilit:
- Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal MetastasisCancer Research, 2012
- An Irradiation-Altered Bone Marrow Microenvironment Impacts Anabolic Actions of PTHEndocrinology, 2011
- Cancer to bone: a fatal attractionNature Reviews Cancer, 2011
- CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosisClinical and Experimental Immunology, 2011
- Preclinical Mouse Models of Human Prostate Cancer and Their Utility in Drug DiscoveryCurrent Protocols in Pharmacology, 2010
- An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammationBlood, 2010
- Circulating CD14+CD16+ monocyte levels predict tissue invasive character of cholangiocarcinomaClinical and Experimental Immunology, 2010
- Healing of non-displaced fractures produced by fatigue loading of the mouse ulnaBone, 2010
- Role of Bcl2 in Osteoclastogenesis and PTH Anabolic Actions in BoneJournal of Bone and Mineral Research, 2008
- Targeting tumor-associated macrophages as a novel strategy against breast cancerJournal of Clinical Investigation, 2006